TILL TRANSAKTIONER
Hälsovård

InNeuroCo has been acquired by Integer

The owners of InNeuroCo has sold the company to Integer (NYSE:ITGR).

Founded in 2014 and headquartered in Pembroke Pines, Florida, InNeuroCo is a leading founder-owned designer and contract manufacturer of ultra-precise, highly engineered neurovascular catheters. InNeuroCo’s primary products are single-use catheters principally used in interventional neurovascular procedures for the treatment of ischemic strokes and aneurysms. Offering turnkey product design and development, supported by comprehensive domestic manufacturing capabilities, InNeuroCo serves as a mission-critical supply partner to the world’s preeminent medical device OEMs.

With approximately US$1.4 billion in annual revenue, Integer is one of the largest medical devices outsource manufacturers in the world, serving the cardiac, vascular, rhythm management and neuromodulation markets.

Oaklins TM Capital in the US served as the exclusive financial advisor to InNeuroCo in its sale to Integer (NYSE:ITGR).

Uppdrag
Företagsförsäljning
Parter
“InNeuroCo’s founders have enjoyed a long-standing history of success with the Oaklins TM healthcare team. When we began contemplating a transaction for InNeuroCo, it was the obvious choice to serve as our advisor. Throughout this transaction, their knowledge of the neurovascular sector, valuable strategic insights and demonstrated expertise in contract medical manufacturing were critical to engineering a successful outcome for InNeuroCo. We appreciate the team’s tireless dedication and thoughtful approach.”

Marc Litzenberg

President and CEO, InNeuroCo

Prata med transaktionsteamet

James McLaren

James McLaren

Managing Director
New York, USA
Oaklins TM Capital
Se profil Kontakta oss
Michael S. Goldman

Michael S. Goldman

Managing Director
New York, USA
Oaklins TM Capital
Se profil Kontakta oss
John Dean

John Dean

Associate Director
Atlanta, USA
Oaklins TM Capital
Se profil Kontakta oss
Bradley S. Goldstein

Bradley S. Goldstein

Associate Director
Atlanta, USA
Oaklins TM Capital
Se profil Kontakta oss
Ariel Fieldman

Ariel Fieldman

Associate
New York, USA
Oaklins TM Capital
Se profil Kontakta oss
Matthew Halbig

Matthew Halbig

Analyst
Atlanta, USA
Oaklins TM Capital
Se profil Kontakta oss

Relaterade transaktioner

Bayer AG has entered into a takeover agreement with Cara Care
Hälsovård | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Lär dig mer
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
Hälsovård

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.

Lär dig mer
Creo Medical Group plc has completed a US$15.7 million equity fundraise
Hälsovård

Creo Medical Group plc has completed a US$15.7 million equity fundraise

Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.

Lär dig mer